May 15 - CTI to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
May 8 - Zevalin Revenues Lead CTI's First Quarter 2008 Financial Results
May 5 - European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
April 30 - CTI Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
April 24 - Veteran Drug Industry Executive to Become President of CTI
More Press Releases
